Antibody-based therapy in colorectal cancer

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Advanced colorectal cancer treatment requires intensive strategies like chemotherapy and monoclonal antibodies (mAbs).
• mAbs show significant antitumor activity through targeted specificity and multiple immune mechanisms.
• Several mAbs are approved or in clinical trials for colorectal cancer, highlighting their therapeutic potential.

Purpose of the Study:

• To review monoclonal antibody (mAb) treatment strategies for colorectal cancer.
• To explore the immunological aspects and mechanisms of action for mAb therapy in colorectal cancer.

Main Methods:

• Review of current literature on monoclonal antibody therapy in colorectal cancer.
• Analysis of immunological mechanisms, including signaling pathway interference, immune cytotoxicity, and immune complex-mediated T-cell induction.
• Discussion of antibodies targeting immune checkpoints.

Main Results:

• mAbs interfere with vital signaling pathways and mediate immune cytotoxicity (ADCC, CDC).
• Immune complexes of mAbs and tumor antigens can enhance tumor-specific CD8+ T-cell responses via APC activation.
• Immune checkpoint-targeting antibodies represent a novel therapeutic approach.

Conclusions:

• Monoclonal antibodies are crucial in advanced colorectal cancer treatment, offering diverse mechanisms for disease control.
• Understanding the immunological aspects of mAb therapy is key to optimizing treatment strategies and developing new therapies.
• Future research should focus on leveraging mAb-mediated immune responses for more effective colorectal cancer management.